Trinkle Professor of Biology Kristian M. Hargadon ’01 and two alumni co-authors published research on anti-tumor immune dysfunction in Cancer Reports.
Health Professionals
Packing lipid nanoparticles with tumor proteins to boost cancer vaccine potency
The concept of using vaccines to treat cancers has been around for several decades. A vaccine was first approved for prostate cancer in 2010, and another was approved in 2015 for melanoma. Since then, many therapeutic—as opposed to preventive—cancer vaccines have been in development, but none are approved. One hurdle is the difficulty in finding antigens in tumors that look foreign enough to trigger an immune response.
Understanding Biomarkers in Early-Stage Melanoma
Hello, everybody. My name is Teresa Amaral, and today I’m here to talk to you about biomarkers. I would like to frame this in relation to the treatment of patients with melanoma, especially early-stage melanoma. Do we have any biomarkers that we could use in the early stage of melanoma?
NCCN Guidelines Update Includes HEPZATO KIT for Uveal Melanoma
Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.